Supporting Statement – Part B

Quality Payment Program/Merit-Based Incentive Payment System (MIPS)

CMS-10621, OMB 0938-1314
Collections of Information Employing Statistical Models

# Introduction

 The Merit-based Incentive Payment System (MIPS) program is one of two tracks for clinicians available through the Quality Payment Program authorized by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program replaced three precursor Medicare reporting programs with a flexible system that allows clinicians to choose from two tracks that link quality to payments: the Merit-Based Incentive Payment System (MIPS) and Advanced Alternative Payment Models (APMs). MIPS assesses MIPS eligible clinicians and groups on the following performance areas: quality – a set of evidence-based, specialty-specific standards; improvement activities that focus on practice-based improvements; cost; and the use of certified Electronic Health Record Technology (CEHRT) to support and promote interoperability and advanced quality objectives in a single, cohesive program that avoids redundancies. Under the APM track, clinicians participating in certain types of APMs (Advanced APMs) may become Qualifying APM participants (QPs) and be excluded from MIPS.

 The primary purpose of this collection is to generate data on a MIPS eligible clinician, group, or subgroup so that CMS can assess MIPS eligible clinician performance in the four performance categories, calculate the final score, and apply performance-based payment adjustments. We will also use this information to provide regular performance feedback to MIPS eligible clinicians and eligible entities. This information will also be made available to beneficiaries, as well as to the general public, on the care compare tool hosted by the U.S. Department of Health and Services. In addition, the data collected under this PRA will be used for research, evaluation, and measure assessment and refinement activities.

 Specifically, CMS uses the data to produce annual statistical reports that provide a comprehensive representation of the overall experience of MIPS eligible clinicians. Further, CMS has processes to monitor and assess measures to ensure their soundness and appropriateness for continued use in the MIPS program. As required by the MACRA, the ongoing measure assessment and monitoring process will be used to refine, add, and drop measures as appropriate, as shown in the proposed changes to the measure sets discussed in the CY 2024 PFS proposed rule. Supporting Statement Part B characterizes the respondents of this collection and any sampling used in data collection so that, when grouped/aggregated data are presented, the inferences that can be drawn from those data are clear.

There are 25 information collections in the CY 2024 PFS proposed rule requirements and burden estimates. The discussion in this Supporting Statement Part B focuses on the 6 information collections for which we plan to conduct statistical reporting and analyses: quality performance category data submitted via Medicare Part B claims, eCQM, and MIPS CQM and QCDR collection types, the quality performance category submissions for MVPs, and data submitted for the Promoting Interoperability and improvement activities performance categories.

# Describe (including a numerical estimate) the potential respondent universe and any sampling or other respondent selection method to be used. Data on the number of entities (e.g., establishments, State and local government units, households, or persons) in the universe covered by the collection and in the corresponding sample are to be provided in tabular form for the universe as a whole and for each of the strata in the proposed sample. Indicate expected response rates for the collection as a whole. If the collection had been conducted previously, include the actual response rate achieved during the last collection.

## Quality Performance Category Data Submission

### Potential respondent universe and response rates

We anticipate that two groups of clinicians will submit quality data under MIPS: those who submit as MIPS eligible clinicians and other eligible clinicians who submit data voluntarily. We estimate the potential respondent universe and response rates for MIPS eligible clinicians and clinicians excluded from MIPS using data from the CY 2021 performance period/2023 MIPS payment year and other CMS sources. To determine which QPs should be excluded from MIPS, we used Advanced APM payment and patient percentages from the APM Participant List for the third snapshot date for the 2022 QP Performance Period. From this data, we calculated the QP determinations as described in the Qualifying APM Participant definition at § 414.1305 for the CY 2024 performance period/2026 MIPS payment year. Due to data limitations, we could not identify specific clinicians who may become QPs in the CY 2024 performance period/2026 MIPS payment year; hence, our model may underestimate or overestimate the fraction of clinicians and allowed charges for covered professional services that will remain subject to MIPS after the exclusions.

We assume that 100 percent of ACO APM Entities will submit quality data to CMS as required under their models. While we do not believe there is additional reporting for ACO APM entities, consistent with assumptions used in the CY 2022 and CY 2023 PFS final rules (86 FR 65577 and 87 FR 70145, respectively), we include all quality data voluntarily submitted by MIPS APM participants made at the individual or TIN-level in our respondent estimates. As stated in the CY 2024 PFS proposed rule we assume non-ACO APM Entities will participate through traditional MIPS and submit as an individual or group rather than as an entity. To estimate who will be a MIPS APM participant that can report using the APM performance pathway (APP) in the CY 2024 performance period/2026 MIPS payment year, we used the final snapshot data from the 2021 QP performance period. We elected to use this data source because the APM participant list for the 2021 final snapshot can reliably be used for MIPS APM participant projections.

As discussed in Supporting Statement A, we assume 820,047 MIPS eligible clinicians would submit data as individual clinicians (both required and voluntary), or as part of groups or APM entities in the CY 2024 performance period/2026 MIPS payment year. Included in this number, we estimate that 9,107 clinicians who exceeded at least one but not all low-volume threshold criteria, elected to opt-in and submitted data in the CY 2021 performance period/2023 MIPS payment year, would elect to opt-in to MIPS in the CY 2024 performance period/2026 MIPS payment year. While 820,047 is the estimated number of MIPS eligible clinicians, the number of respondents that actually submit data varies significantly due to differences in individual, group, virtual group, and APM entity reporting and by the requirements and policies for each performance category.

CMS annual statistical reports about MIPS will be able to provide estimates of the numbers and percentages of MIPS eligible clinicians submitting quality that can be generalized to the entire population of MIPS eligible clinicians, and to relevant subpopulations (such as eligible clinicians participating in MIPS APMs).

### Sampling for quality data submission

For the CY 2024 performance period/2026 MIPS payment year, we finalized the data completeness criteria threshold of at least 75 percent for MIPS eligible clinicians and groups submitting data for the quality performance category (87 FR 70049 through 70052). Tables 1 and 2 summarize the data completeness criteria established for the CY 2024 performance period/2026 MIPS payment year.

**TABLE 1: Summary of Data Completeness Requirements and Performance Period by Collection Type for the CY 2024 Performance Period/2026 MIPS payment year**

| **Collection Type** | **Performance Period** | **Data Completeness** |
| --- | --- | --- |
| Medicare Part B Claims measures  | Jan 1- Dec 31  | For the CY 2024 performance period/ 2026 MIPS payment year, 75 percent sample of individual MIPS eligible clinician’s, group’s or subgroup’s Medicare Part B patients for the performance period. |
| Administrative claims measures | Jan 1- Dec 31 | 100 percent sample of individual MIPS eligible clinician’s Medicare Part B patients for the performance period. |
| QCDR measures, MIPS CQMs, and eCQMs  | Jan 1- Dec 31  | For the CY 2024 performance period/2026 MIPS payment year, 75 percent sample of individual MIPS eligible clinician’s, group’s or subgroup’s patients across all payers for the performance period. |
| CAHPS for MIPS survey measure | Jan 1- Dec 31  | Sampling requirements for the group’s and subgroup’s Medicare Part B patients |

**TABLE 2: Summary of Quality Data Submission Criteria for the CY 2024 Performance Period/2026 MIPS Payment Year for Individual Clinicians and Groups**

| **Clinician Type** | **Submission Criteria** | **Measure Collection Types (or Measure Sets) Available for Submission (Excludes Administrative Claims)** |
| --- | --- | --- |
| Individual Clinicians | Report at least six measures including one outcome measure, or if an outcome measure is not available report another high priority measure; if fewer than six measures apply then report on each measure that is applicable. Clinicians would need to meet the applicable data completeness standard for the applicable performance period for each collection type. | Individual MIPS eligible clinicians select their measures from the following collection types: Medicare Part B claims measures (individual clinicians in small practices only), MIPS CQMs, QCDR measures, eCQMs, or reports on one of the specialty measure sets if applicable. |
| Groups | Report at least six measures including one outcome measure, or if an outcome measure is not available report another high priority measure; if less than six measures apply then report on each measure that is applicable. Clinicians would need to meet the applicable data completeness standard for the applicable performance period for each collection type. | Groups select their measures from the following collection types: Medicare Part B claims measures (small practices only), MIPS CQMs, QCDR measures, eCQMs, or the CAHPS for MIPS survey - or reports on one of the specialty measure sets if applicable.  |
| MVP Participant  | An MVP Participant must select and report four quality measures, including one outcome measure (or, if an outcome measure is not available, one high priority measure, included in the MVP.  | MVP Participants (individual MIPS eligible clinician, single specialty group, multispecialty group, subgroup, or APM Entity that is assessed on an MVP) report on the applicable measures and activities in MVPs included in the MVP Inventory.  |

## Data Submission for Promoting Interoperability and Improvement Activities Performance Categories

During the CY 2024 performance period/2026 MIPS payment year, eligible clinicians, groups, subgroups and APM Entities can submit Promoting Interoperability and improvement activities data through direct, log in and upload, or log in and attest submission types.

Based on the CY 2021 performance period/2023 MIPS payment year and CY 2020 performance period/2022 MIPS payment year eligibility data, we estimate that a total of 30, 107 MIPS eligible clinicians (22,293 individual MIPS eligible clinicians, 7,794 groups, and 20 subgroups) would submit Promoting Interoperability data for the CY 2024 performance period/2026 MIPS payment year. These estimates reflect that certain MIPS eligible clinicians will qualify for automatic reweighting of the Promoting Interoperability performance category to zero percent, including MIPS eligible clinicians who are hospital-based, ambulatory surgical center-based, small practices, non-patient facing clinicians, physical therapists; occupational therapists; qualified speech-language pathologists or qualified audiologist; clinical psychologists; registered dieticians or nutrition professionals and clinical social workers.

As discussed in Supporting Statement A, a variety of organizations will submit Promoting Interoperability data on behalf of clinicians. Clinicians not participating in a MIPS APM may submit data as individuals or as part of a group. In the CY 2017 Quality Payment Program final rule (81 FR 77258 through 77260, 77262 through 77264) and CY 2019 PFS final rule (83 FR 59822-59823), we established that eligible clinicians in MIPS APMs (including the Shared Savings Program) may report for the Promoting Interoperability performance category as an APM Entity group, individuals, or a group. In the CY 2023 PFS final rule, we finalized a voluntary reporting option for APM Entities to report the Promoting Interoperability performance category at the APM Entity level beginning with the CY 2023 performance period/2025 MIPS payment year (87 FR 70087 and 70088). We also finalized in the CY 2022 PFS final rule that a subgroup reporting measures and activities in an MVP must submit its affiliated group’s data for the Promoting Interoperability performance category (86 FR 65413 through 65414).

As discussed in Supporting Statement A, we estimate 31,743 individually eligible clinicians, 12,373 groups and virtual groups, and 20 subgroups will submit improvement activities on behalf of clinicians during the CY 2024 performance period/2026 MIPS payment year for a total of 44,136 submissions to the improvement activities performance category.

# Describe the procedures for the collection of information including:

# Statistical methodology for stratification and sample selection,

# Estimation procedure,

# Degree of accuracy needed for the purpose described in the justification,

# Unusual problems requiring specialized sampling procedures, and

# Any use of periodic (less frequent than annual) data collection cycles to reduce burden.

There are 25 information collections in the 2024 PRA package. We do not anticipate using sampling or statistical estimation in the information collections.

# Describe methods to maximize response rates and to deal with issues of non-response. The accuracy and reliability of information collected must be shown to be adequate for intended uses. For collections based on sampling, a special justification must be provided for any collection that will not yield 'reliable' data that can be generalized to the universe studied.

## Quality Performance Category Data Submission

We expect additional experience with submissions under MIPS to clarify optimal data completeness thresholds and submission criteria for use in future performance periods. We will continually evaluate our policies and notify the public through future notice and comment rulemaking if we make substantive changes. As we evaluate our policies, we plan to continue a dialogue with interested parties to discuss opportunities for program efficiency and flexibility.

We believe that by continuing to provide virtual group participation as an option we will experience continued improvement in response rates due to the ability to better pool resources from participating as part of a virtual group, allowing for reporting on 6 quality measures.

## Promoting Interoperability Performance Category Data Submission

The revised scoring methodology finalized in the CY 2019 PFS final rule (83 FR 59791) has provided a simpler, more flexible, less burdensome structure, allowing MIPS eligible clinicians to put their focus back on patients. This scoring methodology, in effect for the CY 2024 performance period/2026 MIPS payment year, encourages MIPS eligible clinicians to push themselves on measures that are most applicable to how they deliver care to patients, instead of focusing on measures that may not be as applicable to them. We believe the increased flexibility to MIPS eligible clinicians that enables them to focus more on patient care and health data exchange through interoperability will continue to help to maximize response rates for the Promoting Interoperability performance category.

In the CY 2020 PFS final rule (86 FR 65542), we required QCDRs and qualified registries to be able to submit data for each of the quality, improvement activities, and Promoting Interoperability performance categories with the stipulation that based on the amendment to § 414.1400(a)(2)(iii) a third party could be excepted from this requirement if its MIPS eligible clinicians, groups or virtual groups fall under the reweighting policies at § 414.1380(c)(2)(i)(A)(4) or § 414.1380(c)(2)(i)(C)(1) through (7) or § 414.1380(c)(2)(i)(C)(9) through (11). As a result, MIPS reporting for clinicians who utilized qualified registries or QCDR that have not previously offered the ability to report performance categories other than quality will be able to report MIPS data in a more streamlined and less burdensome manner.

## Improvement Activities Performance Category Data Submission

User experiences from the CY 2019 performance period/2021 MIPS payment year reflect that the majority of users submit improvement activities data as part of the login and upload or direct submission types which allow data for multiple performance categories (i.e., quality and Promoting Interoperability) to be submitted at once. This results in less additional required time to submit improvement activities data which consists of manually attesting certain activities were performed. In addition, the same improvement activity may be reported across multiple performance periods so many MIPS eligible clinicians may submit the same information for the CY 2024 performance period/2026 MIPS payment year as they did for previous MIPS performance periods/MIPS payment years. There is also financial incentive to submit improvement activities data, as clinicians would not receive credit in their MIPS final score otherwise. We believe a less burdensome user experience combined with the financial incentives for submitting improvement activities data will continue to improve response rates in the CY 2024 performance period/2026 MIPS payment year.

# Describe any tests of procedures or methods to be undertaken. Testing is encouraged as an effective means of refining collections of information to minimize burden and improve utility. Tests must be approved if they call for answers to identical questions from 10 or more respondents. A proposed test or set of tests may be submitted for approval separate­ly or in combination with the main collection of information.

 We are refining our procedures, methods and testing over time to be more efficient. We do not have any additional testing to describe in this section, including no additional tests that call for answers to identical questions from 10 or more respondents.

As stated above, we expect that additional experience with MIPS will clarify optimal reporting thresholds and submission criteria for use in future performance periods across the quality, Promoting Interoperability, and improvement activities performance categories. We will continually evaluate our policies based on our analysis of MIPS and other data.

# Provide the name and telephone number of individuals consulted on statistical aspects of the design and the name of the agency unit, contractor(s), grantee(s), or other person(s) who will actually collect and/or analyze the information for the agency.

 We do not anticipate any additional statistical reporting on data other than that presented here for the quality or Promoting Interoperability and improvement activities performance categories.

## Quality, Promoting Interoperability, and Improvement Activities Performance Category Data

 We anticipate that a contractor will analyze information collected from individual MIPS eligible clinicians, groups, subgroups, and APM Entities submitting data to the quality, Promoting Interoperability and improvement activities performance categories.